(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of 12.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.47%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.58%.
Moderna's revenue in 2026 is $2,228,000,000.On average, 26 Wall Street analysts forecast MRNA's revenue for 2026 to be $855,961,746,016, with the lowest MRNA revenue forecast at $768,129,850,436, and the highest MRNA revenue forecast at $903,071,580,918. On average, 25 Wall Street analysts forecast MRNA's revenue for 2027 to be $992,899,655,943, with the lowest MRNA revenue forecast at $749,365,763,653, and the highest MRNA revenue forecast at $1,379,359,996,495.
In 2028, MRNA is forecast to generate $1,278,752,552,467 in revenue, with the lowest revenue forecast at $857,558,689,572 and the highest revenue forecast at $1,908,347,549,420.